JAGX Jaguar Health, Inc. Stock Quote

JAGX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.29	Insider Own	0.30%	Shs Outstand	44.71M	Perf Week	-2.87%
Market Cap	21.96M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	7.66%	Shs Float	-	Perf Month	-19.28%
Income	-58.60M	PEG	-	EPS next Q	-0.22	Inst Own	9.00%	Short Float	-	Perf Quarter	-45.11%
Sales	5.70M	P/S	3.85	EPS this Y	60.80%	Inst Trans	17.41%	Short Ratio	1.82	Perf Half Y	-71.46%
Book/sh	0.18	P/B	1.63	EPS next Y	21.90%	ROA	-99.70%	Target Price	10.88	Perf Year	-93.80%
Cash/sh	0.23	P/C	1.25	EPS next 5Y	40.00%	ROE	-321.00%	52W Range	0.27 - 5.16	Perf YTD	-71.73%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-104.20%	52W High	-94.03%	Beta	1.80
Dividend %	-	Quick Ratio	1.20	Sales past 5Y	98.30%	Gross Margin	61.50%	52W Low	14.15%	ATR	0.03
Employees	52	Current Ratio	1.50	Sales Q/Q	116.70%	Oper. Margin	-	RSI (14)	42.36	Volatility	11.38% 8.82%
Optionable	Yes	Debt/Eq	3.96	EPS Q/Q	-40.00%	Profit Margin	-	Rel Volume	0.33	Prev Close	0.29
Shortable	No	LT Debt/Eq	3.10	Earnings	-	Payout	-	Avg Volume	2.44M	Price	0.31
Recom	1.50	SMA20	-2.67%	SMA50	-18.91%	SMA200	-69.31%	Volume	814,269	Change	4.83%

Jul-07-21

Initiated

Cantor Fitzgerald

Overweight

Jul-11-17

Initiated

Rodman & Renshaw

Buy

Jul-01-22 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE
Jun-29-22 08:30AM	Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China ACCESSWIRE
Jun-22-22 08:30AM	Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi ACCESSWIRE
Jun-21-22 08:30AM	Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1 ACCESSWIRE +6.04%
Jun-13-22 08:30AM	Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cancer Patients ACCESSWIRE -12.13%
Jun-10-22 04:15PM	Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders ACCESSWIRE
08:30AM	Jaguar Health to Participate in BIO International Convention (BIO 2022) ACCESSWIRE
Jun-09-22 08:30AM	Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications ACCESSWIRE
08:30AM	Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications CNW Group
May-25-22 08:30AM	Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition ACCESSWIRE
May-24-22 08:30AM	Jaguar Health Announces Presentation of an Investigator-initiated Evaluation of Crofelemer for a Severe Congenital Diarrheal Disorder at 2022 Digestive Disease Week ACCESSWIRE
May-23-22 07:00AM	Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index ACCESSWIRE
May-19-22 08:30AM	Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd! ACCESSWIRE
May-17-22 08:55AM	Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd! ACCESSWIRE
May-11-22 02:30PM	TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health ACCESSWIRE
08:30AM	Jaguar Health Announces Launch of Mytesi Telehealth Program ACCESSWIRE
May-10-22 08:00AM	Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials ACCESSWIRE
May-06-22 04:15PM	Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE -5.28%
May-05-22 02:15PM	UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates ACCESSWIRE
08:30AM	Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates ACCESSWIRE
May-03-22 08:30AM	Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs ACCESSWIRE
Apr-27-22 10:20AM	Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESSWIRE +6.99%
Apr-20-22 08:30AM	Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022 ACCESSWIRE
Apr-15-22 04:15PM	Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE
Apr-06-22 08:30AM	Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico ACCESSWIRE -8.43%
Apr-05-22 08:30AM	Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer ACCESSWIRE -7.65%
Mar-31-22 06:30AM	Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets ACCESSWIRE +32.28%
Mar-14-22 01:15PM	Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast ACCESSWIRE
Mar-11-22 05:00PM	Jaguar Health Provides Company Updates and Reports 2021 Financials ACCESSWIRE
Mar-07-22 08:30AM	Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates ACCESSWIRE -5.28%
Mar-01-22 08:30AM	Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas ACCESSWIRE
Feb-16-22 08:30AM	Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs ACCESSWIRE
Feb-15-22 08:30AM	Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency ACCESSWIRE +6.16%
Feb-10-22 08:30AM	Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs ACCESSWIRE Test RSS -9.44%
08:30AM	Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs ACCESSWIRE
Feb-01-22 08:30AM	Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD) ACCESSWIRE
Jan-24-22 08:30AM	Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics ACCESSWIRE
Jan-13-22 08:30AM	Jaguar Health Provides Corporate Update and Outlines 2022 Milestones ACCESSWIRE -6.86%
Jan-12-22 08:58AM	JAGX Stock Alert: What Is Going on With Jaguar Health Today? InvestorPlace +9.68%
08:30AM	Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida ACCESSWIRE
07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday InvestorPlace
Jan-04-22 08:30AM	Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESSWIRE
Dec-22-21 08:30AM	Jaguar Health Shares Comments from FDAs December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESSWIRE -14.49%
05:55AM	FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs Benzinga
Dec-21-21 03:38PM	JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher InvestorPlace +20.00%
01:50PM	Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA ACCESSWIRE
Dec-20-21 08:30AM	Jaguar Healths Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Companys Focus on Rare Diseases & Orphan Drugs ACCESSWIRE
Dec-13-21 08:30AM	European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Healths Italian Subsidiary, for Short Bowel Syndrome ACCESSWIRE -5.47%
Dec-10-21 08:00AM	Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021) ACCESSWIRE
Dec-06-21 08:30AM	Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Companys Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021) ACCESSWIRE
Nov-19-21 02:21PM	Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients Benzinga
09:20AM	Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients ACCESSWIRE
Nov-17-21 08:00AM	Jaguar Health Reports 2021 Third Quarter Financial Results ACCESSWIRE -6.90%
Nov-16-21 08:30AM	Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager ACCESSWIRE -5.43%
Nov-15-21 07:00AM	Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time ACCESSWIRE
Nov-10-21 08:30AM	Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates ACCESSWIRE -6.47%
Nov-08-21 08:30AM	Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer ACCESSWIRE
Nov-02-21 08:30AM	Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch ACCESSWIRE
Nov-01-21 08:30AM	The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed ACCESSWIRE
Oct-29-21 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE
Oct-28-21 04:50AM	64 Biggest Movers From Yesterday Benzinga
Oct-27-21 12:00PM	44 Stocks Moving In Wednesday's Mid-Day Session Benzinga -17.34%
Oct-25-21 08:30AM	Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing ACCESSWIRE +11.60%
Oct-07-21 09:45AM	Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A. ACCESSWIRE
Sep-30-21 08:30AM	Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award ACCESSWIRE +6.07%
Sep-27-21 08:30AM	Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021 ACCESSWIRE
Sep-23-21 08:30AM	Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESSWIRE +6.55%
Sep-16-21 08:30AM	REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time ACCESSWIRE
Sep-15-21 08:30AM	Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency ACCESSWIRE
Sep-14-21 08:30AM	Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market ACCESSWIRE -6.00%
Sep-09-21 08:30AM	Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director ACCESSWIRE
Sep-07-21 02:32PM	Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher Benzinga -17.24%
12:12PM	Mid-Day Market Update: Gold Drops 2%; Pliant Therapeutics Shares Jump Benzinga
Sep-03-21 04:15PM	Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split ACCESSWIRE
12:00PM	Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders ACCESSWIRE
Aug-23-21 08:30AM	Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting ACCESSWIRE
Aug-19-21 08:30AM	Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe ACCESSWIRE
Aug-17-21 08:30AM	Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea ACCESSWIRE
Aug-13-21 09:00PM	Jaguar Animal Health (JAGX) Q2 2021 Earnings Call Transcript Motley Fool -6.77%
07:30AM	Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results ACCESSWIRE
Aug-10-21 04:30PM	Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time ACCESSWIRE
08:30AM	Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates ACCESSWIRE
Aug-06-21 04:15PM	Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote ACCESSWIRE
Jul-28-21 08:30AM	REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates ACCESSWIRE
Jul-26-21 08:30AM	Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates ACCESSWIRE
Jul-23-21 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE
Jul-19-21 08:30AM	Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing ACCESSWIRE +10.69%
Jul-14-21 08:30AM	Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients ACCESSWIRE -10.07%
Jul-09-21 04:15PM	Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote ACCESSWIRE
Jun-23-21 08:30AM	Jaguar Health Set to Join Russell Microcap Index ACCESSWIRE
Jun-22-21 07:17PM	Is Jaguar Health, Inc. (JAGX) A Good Stock To Buy? Insider Monkey
Jun-11-21 04:15PM	Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote ACCESSWIRE
Jun-04-21 04:15PM	Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE
Jun-02-21 08:30AM	REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern ACCESSWIRE
Jun-01-21 08:30AM	Napo EU S.p.A., Jaguar Healths Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU ACCESSWIRE +12.50%
08:30AM	Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC ACCESSWIRE
May-26-21 08:30AM	Napo Pharmaceuticals, Jaguar Healths Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer ACCESSWIRE +11.84%
May-20-21 08:30AM	Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting ACCESSWIRE +5.04%
May-19-21 11:00AM	Jaguar Animal Health (JAGX) Q1 2021 Earnings Call Transcript Motley Fool
08:30AM	Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community ACCESSWIRE

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lizak Carol R.	Chief Financial Officer	Sep 13	Buy	2.51	7,968	20,000	7,968	Mar 30 09:32 PM
CONTE LISA A	CEO and President	Sep 13	Buy	2.51	7,968	20,000	8,003	Mar 30 09:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience